Canada Approves First Generic Semaglutide, Opening a New GLP-1 Access Era

What Happened

Health Canada has granted marketing authorization for Sandoz Semaglutide — the first generic version of Ozempic approved in Canada. The GLP-1 receptor agonist injection is indicated for once-weekly subcutaneous administration in adults with type 2 diabetes to improve glycemic control, delivered in two pen presentations covering the starter and maintenance ranges of the reference product.

The approval marks "an important step towards expanding patient access to an affordable semaglutide treatment option in Canada," Sandoz said, and builds on two other recent company GLP-1 milestones: the U.S. FDA's acceptance of Sandoz's applications for its in-house developed generic tirzepatide, and Brazilian approval of Owozy, a Sandoz semaglutide.

Who Is Affected

Nearly six million Canadians live with diabetes, roughly 90 to 95 percent of it type 2, and prevalence is projected to reach 7.3 million by 2034. The Canadian GLP-1 market is worth an estimated USD 2.6 billion annually, with close to 12 million semaglutide injection pens used each year. Patients paying out of pocket and provincial drug plans both stand to benefit from generic pricing pressure — although Sandoz says the approval has no impact on its 2026 financial guidance and it foresees no material contribution this year from any launch.

Timeline

• 2025 — FDA accepts Sandoz applications for its in-house developed generic tirzepatide
• Earlier 2026 — Owozy semaglutide approved in Brazil
• September 18, 2026 — Health Canada authorizes Sandoz Semaglutide
• Coming months — launch timing and pricing to be announced

What This Means for Researchers

First-generation GLP-1 patents are beginning to crack, in sequence: Brazil first, Canada second, U.S. generic applications pending. For the research community, generic entry reshapes the sourcing landscape — lower prices historically attract more counterfeit and substandard copies riding on legitimate brands' reputations.

"GLP-1s represent one of the most significant access opportunities in modern healthcare," said Sandoz CEO Richard Saynor. "As demand for these medicines continues to rise globally, Sandoz remains focused on bringing affordable treatment options that expand access to patients." Every access expansion multiplies the volume of semaglutide moving through unofficial channels, which makes independent batch verification more valuable, not less.

How to Verify Your Peptides

Generic or branded, every vial deserves the same scrutiny: review certificates of analysis, use third-party lab testing, compare HPLC and LC-MS methods, and see our semaglutide purity testing guide.

Safe Alternatives

See our semaglutide profile for the compound's evidence base, our semaglutide dosage calculator for reconstitution planning, and our vetted vendor directory for suppliers with published test results.

Sources

Company announcements; regulatory decisions.